Latest news with #UlcerativeColitis

Malaysian Reserve

2 days ago

Business
Malaysian Reserve

Interleukin-23 Inhibitors Market to Surge During the Forecast Period (2025-2034) Due to Demand for Targeted Autoimmune Therapies

The interleukin-23 inhibitors market is witnessing robust growth driven by the rising prevalence of autoimmune diseases like psoriasis and inflammatory bowel disease. Advancements in biologics and increased adoption of targeted therapies are further accelerating demand. Favorable reimbursement policies and growing awareness among healthcare providers are also contributing to market expansion. The IL-23 inhibitors market is expected to maintain strong momentum with ongoing R&D and label expansions. LAS VEGAS, Aug. 14, 2025 /PRNewswire/ — DelveInsight's Interleukin-23 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Ulcerative Colitis, Crohn's Disease, Psoriasis, Parkinson's Disease, Alzheimer's Disease, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging interleukin-23 inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the Interleukin-23 Inhibitors Market Report As per DelveInsight's analysis, the total market size of interleukin-23 inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Ulcerative Colitis, Crohn's Disease, Psoriasis, Parkinson's Disease, Alzheimer's Disease, and others. Leading interleukin-23 inhibitor companies, such as Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, SFA Therapeutics, BioVie, and others, are developing novel Interleukin-23 inhibitors that can be available in the interleukin-23 inhibitors market in the coming years. Some of the key interleukin-23 inhibitors in the pipeline include Icotrokinra (JNJ-77242113), SFA-002, Bezisterim (NE3107), and others. In April 2025, Johnson & Johnson released new Icotrokinra data from a subgroup analysis of ICONIC-LEAD in moderate-to-severe plaque psoriasis to assess the efficacy and safety of systemic therapy in adolescents and adults simultaneously. These data were presented at the 2025 WCPD annual meeting. In March 2025, SFA Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida. In March 2025, SFA Therapeutics announced positive data from its Phase Ib clinical trial of SFA-002, an oral treatment for mild-to-moderate chronic plaque psoriasis. The study met its primary endpoint of safety, with no TRAEs or toxicities observed during the treatment period, and no rebound effects were noted. In March 2025, Sun Pharmaceuticals announced presentation of a Phase IIIb, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of ILUMYA for the treatment of moderate-to-severe psoriasis affecting the nails, results, at the 2025 American Academy of Dermatology (AAD) conference. In February 2025, Johnson & Johnson announced the submission of TREMFYA for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis to the European Medicines Agency (EMA). Discover which indication is expected to grab the major interleukin-23 inhibitors market share @ Interleukin-23 Inhibitors Market Report Interleukin-23 Inhibitors Market Dynamics The interleukin-23 inhibitors market has seen significant growth in recent years, driven primarily by the increasing global burden of autoimmune diseases such as psoriasis, psoriatic arthritis, and inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. Targeted therapies that inhibit the IL-23 pathway, particularly those that block the p19 subunit, have demonstrated superior efficacy and safety profiles compared to older biologics, thus gaining rapid adoption among healthcare providers and patients. A key driver of this market is the successful commercialization of biologics such as SKYRIZI, TREMFYA, ILUMYA/ILUMETRI, and the more recent OMVOH, which specifically target the IL-23 p19 subunit. These agents offer improved disease control, convenient dosing schedules, and lower immunogenicity, which enhances long-term adherence. Additionally, their favorable safety profiles relative to older tumor necrosis factor (TNF) inhibitors have made them attractive options, particularly for patients who fail to respond to first-line treatments. Continued clinical success, coupled with positive real-world outcomes data, has further solidified their position in treatment algorithms. Despite the growth potential, the IL-23 inhibitors market also faces certain restraints and challenges. The high cost of biologic therapies can limit patient access, particularly in low- and middle-income countries where reimbursement and insurance coverage are limited. Biosimilar development remains a potential future threat, although the structural complexity of monoclonal antibodies like IL-23 inhibitors presents higher barriers to entry for biosimilar manufacturers compared to small molecules. Additionally, competition from other targeted pathways such as IL-17, IL-12/23 dual inhibitors, and emerging oral small molecules (e.g., JAK inhibitors and TYK2 inhibitors) may impact market share over time. On the innovation front, ongoing clinical research is expanding the potential of IL-23 inhibitors beyond dermatology and gastroenterology. Several studies are investigating their utility in axial spondyloarthritis, hidradenitis suppurativa, and even systemic lupus erythematosus. Moreover, pharmaceutical companies are exploring combination therapies and long-acting formulations to differentiate their products and enhance patient outcomes. These efforts are likely to diversify the application landscape and reinforce market momentum. In summary, the IL-23 inhibitors market is poised for sustained growth, underpinned by robust clinical efficacy, expanding indications, and continued physician and patient preference for targeted biologics. However, manufacturers must navigate cost-related barriers, evolving competition, and regulatory complexities to maintain their competitive edge in this dynamic therapeutic space. Interleukin-23 Inhibitors Treatment Market Currently, multiple IL-23 inhibitors are available in the market, with recent introductions including OMVOH (mirikizumab-mrkz), SKYRIZI (risankizumab-rzaa), ILUMYA/ILUMETRI (tildrakizumab-asmn), TREMFYA (guselkumab), and others. SKYRIZI is an IL-23 inhibitor that specifically targets the p19 subunit of the IL-23 cytokine. It is a biologic therapy approved for use in North America, the EU, and Japan for the treatment of psoriatic conditions such as psoriasis and psoriatic arthritis. The drug is administered via subcutaneous injection every three months, following two initial loading doses. SKYRIZI is a humanized IgG1 monoclonal antibody that binds selectively to the p19 subunit, blocking IL-23's interaction with its receptor and thereby suppressing the release of pro-inflammatory cytokines and chemokines. In April 2019, the US FDA approved SKYRIZI for treating moderate-to-severe plaque psoriasis. The same year, the European Commission also approved its use for adult patients eligible for systemic therapy. In March 2019, AbbVie announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved SKYRIZI for treating plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis in adults with inadequate response to standard therapies. ILUMYA, another IL-23 inhibitor, is a humanized IgG1/k monoclonal antibody that also selectively binds to the p19 subunit of IL-23, blocking its receptor interaction and reducing the release of pro-inflammatory mediators. In May 2018, the US FDA approved ILUMYA for adults with moderate-to-severe plaque psoriasis who are suitable candidates for systemic treatment or phototherapy. Later, in September 2018, Sun Pharmaceuticals announced that its European partner, Almirall, received European Commission approval to market ILUMETRI for adults with moderate-to-severe chronic plaque psoriasis. In September 2020, Sun Pharma also launched ILUMYA in Japan for adults with plaque psoriasis unresponsive to conventional therapies. Learn more about the interleukin-23 inhibitors @ Interleukin-23 Inhibitors Analysis Key Emerging Interleukin-23 Inhibitors and Companies IL-23 inhibitors have a pipeline consisting of products such as icotrokinra (JNJ-77242113), SFA-002, bezisterim (NE3107), and others, which are in late Phases (III and II). Icotrokinra is the first oral peptide specifically engineered to target and inhibit the IL-23 receptor, a key driver of inflammation in moderate-to-severe plaque psoriasis. It also shows promise in treating other diseases mediated by IL-23. The compound binds to the IL-23 receptor with exceptionally high affinity (in the single-digit picomolar range) and effectively suppresses IL-23 signaling in human T cells with high selectivity. The molecule emerged from a 2017 licensing and collaboration agreement between Protagonist Therapeutics and Johnson & Johnson, which aimed to discover and develop next-generation therapeutics. In May 2024, Johnson & Johnson shared new findings from the Phase III ICONIC-TOTALa trial evaluating icotrokinra in adults and adolescents (aged 12 and above) with as little as 1% body surface area involvement and at least moderate plaque psoriasis affecting sensitive, high-impact areas. According to the company's Q1 2025 earnings presentation, additional Phase III data from the ICONIC-LEAD, ICONIC-ADVANCE 1/2, and ICONIC-TOTAL studies are expected later in 2025. SFA-002 is a novel, first-in-class oral immunomodulator designed to treat autoimmune diseases, beginning with mild-to-moderate chronic plaque psoriasis. Unlike current treatments that suppress a single inflammatory pathway, SFA-002 simultaneously downregulates several key proinflammatory cytokines, TNF-α, IL-23, IL-10, IL-12, IL-17, and IFN-γ, while modulating the immune response. This multi-pathway mechanism provides a broader therapeutic effect without the immunosuppressive risks of injectable therapies. Currently in Phase Ib clinical trials, SFA-002 has shown strong efficacy with an excellent safety profile and no reported adverse events, positioning it as a potential game-changer in the treatment of autoimmune conditions. The anticipated launch of these emerging therapies are poised to transform the interleukin-23 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the interleukin-23 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about interleukin-23 inhibitors clinical trials, visit @ Interleukin-23 Inhibitors Treatment Interleukin-23 Inhibitors Overview Interleukin-23 (IL-23) inhibitors are monoclonal antibodies that specifically target the p19 subunit of IL-23, a key cytokine responsible for the activation and persistence of Th17 cells. By blocking IL-23 signaling, these agents reduce the production of pro-inflammatory cytokines like IL-17A, IL-17F, and IL-22, thereby controlling inflammation and slowing the progression of immune-mediated disorders. These inhibitors are approved for treating moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, particularly in patients who have not responded adequately to traditional systemic therapies or TNF-α inhibitors. Their therapeutic effect is primarily achieved through disruption of the IL-23/Th17 pathway, a critical driver of chronic inflammation in these conditions. Inhibiting IL-23 results in reduced Th17 cell activity and cytokine release, leading to marked clinical improvement. Interleukin-23 Inhibitors Epidemiology Segmentation The interleukin-23 inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases of Selected Indications for IL-23 Inhibitor Total Eligible Patient Pool of Selected Indications for IL-23 Inhibitor Total Treated Cases of Selected Indications for IL-23 Inhibitor Interleukin-23 Inhibitors Report Metrics Details Study Period 2020–2034 Interleukin-23 Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Ulcerative Colitis, Crohn's Disease, Psoriasis, Parkinson's Disease, Alzheimer's Disease, and others Key Interleukin-23 Inhibitors Companies Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, SFA Therapeutics, BioVie, Eli Lilly, AbbVie, Boehringer Ingelheim, Sun Pharmaceutical, Almirall, and others Key Interleukin-23 Inhibitors Icotrokinra (JNJ-77242113), SFA-002, Bezisterim (NE3107), OMVOH, SKYRIZI, ILUMYA/ILUMETRI, TREMFYA, and others Scope of the Interleukin-23 Inhibitors Market Report Interleukin-23 Inhibitors Therapeutic Assessment: Interleukin-23 Inhibitors current marketed and emerging therapies Interleukin-23 Inhibitors Market Dynamics: Conjoint Analysis of Emerging Interleukin-23 Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Interleukin-23 Inhibitors Market Access and Reimbursement Discover more about interleukin-23 inhibitors in development @ Interleukin-23 Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary of Interleukin-23 (IL-23) Inhibitors 4 Key Events 5 Epidemiology and Market Forecast Methodology of IL-23 Inhibitor 6 IL-23 Inhibitor Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies in 2025 6.2 Market Share (%) Distribution by Therapies in 2034 6.3 Market Share (%) Distribution by Indications in 2025 6.4 Market Share (%) Distribution by Indications in 2034 7 IL-23 Inhibitor: Background and Overview 7.1 Introduction 7.2 Potential of IL-23 Inhibitor in Different Indications 7.3 Clinical Applications of IL-23 Inhibitor 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.4 Total Cases of Selected Indications for IL-23 Inhibitor in the 7MM 8.5 Total Eligible Patient Pool of IL-23 Inhibitor in Selected Indications in the 7MM 8.6 Total Treated Cases of Selected Indications for IL-23 Inhibitor in the 7MM 9 Marketed Products of IL-23 Inhibitor 9.1 Key Competitors 9.2 SKYRIZI (risankizumab-rzaa): AbbVie/Boehringer Ingelheim 9.2.1 Product Description 9.2.2 Regulatory Milestones 9.2.3 Other Developmental Activities 9.2.4 Clinical Development 9.2.4.1 Clinical Trial Information 9.2.5 Safety and Efficacy 9.2.6 Analyst Views 9.3 ILUMYA/ILUMETRI (tildrakizumab-asmn): Sun Pharma List to be continued in the final report… 10 Emerging Therapies of IL-23 Inhibitor 10.1 Key Competitors 10.2 Icotrokinra (JNJ-77242113): Johnson & Johnson/ Innovative Medicine/Protagonist Therapeutics 10.2.1 Product Description 10.2.2 Other Developmental Activities 10.2.3 Clinical Development 10.2.3.1 Clinical Trial Information 10.2.4 Safety and Efficacy 10.2.5 Analyst Views 10.3 SFA-002: SFA Therapeutics List to be continued in the final report… 11 IL-23 Inhibitor: Seven Major Market Analysis 11.1 Key Findings 11.2 Market Outlook of IL-23 Inhibitor 11.3 Conjoint Analysis of IL-23 Inhibitor 11.4 Key Market Forecast Assumptions of IL-23 Inhibitor 11.4.1 Cost Assumptions and Rebates 11.4.2 Pricing Trends 11.4.3 Analogue Assessment 11.4.4 Launch Year and Therapy Uptakes 11.5 Total Market Size of IL-23 Inhibitor in the 7MM 11.6 Market Size of IL-23 Inhibitor by Indication in the7MM 11.7 The United States Market Size 11.7.1 Total Market Size of IL-23 Inhibitors in the US 11.7.2 Market Size of IL-23 Inhibitor by Indication in the US 11.7.3 Market Size of IL-23 Inhibitor by Therapies in the US 11.8 EU4 and the UK Market Size 11.9 Japan Market Size 12 Market Access and Reimbursement of IL-23 Inhibitors 13 SWOT Analysis of IL-23 Inhibitors 14 KOL Views of IL-23 Inhibitors 15 Unmet Needs of IL-23 Inhibitors 16 Bibliography 17 Report Methodology Related Reports Interleukin-2 Inhibitors Market Interleukin-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key IL-2 inhibitors companies, including Mural Oncology, Corvus Pharmaceuticals, Philogen, Merck, Nektar, Cue Biopharma, Krystal Biotech, ILTOO Pharma, Innovent, Regeneron Pharmaceuticals, R2T Biopharma (XEME Biopharma), AstraZeneca, GI Innovation, Merck, R2T Biopharma (XEME Biopharma), Sanofi, Synthekine, BioNTech, Medicenna Therapeutics, Ascendis Pharma, Sanofi, Synthorx, Cugene, AbbVie, Deka Biosciences, Dragonfly Therapeutics, Werewolf Therapeutics, Xilio Therapeutics, Bioniz Therapeutics, Equillium, Asher Bio, Synthekine, Anaveon, Aulos Bioscience, Selecxine, ProBio, Hoffmann-La Roche, TILT Biotherapeutics, among others. Crohn's Disease Market Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies, including RedHill Biopharma, Arena Pharmaceuticals, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, Morphic Therapeutics, NImmune, Avobis Bio, Alimentiv, Abivax S.A., Roche, Mesoblast, Takeda, AstraZeneca, among others. Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, among others. Psoriasis Market Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriasis companies, including UCB Pharma, Novartis, Alumis, SFA Therapeutics, Amgen, AbbVie, Can-Fite BioPharma, Johnson & Johnson, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:

Ulcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline

Globe and Mail

4 days ago

Health
Globe and Mail

Ulcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline

The Ulcerative Colitis treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions by companies such as Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck and Mesoblast, among others. DelveInsight's " Ulcerative Colitis Market Insight, Epidemiology And Market Forecast - 2034" report delivers comprehensive insights into the ulcerative colitis market dynamics, epidemiological trends, and treatment landscape across the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The ulcerative colitis market size in the 7MM was USD 8.4 billion in 2023, with the United States accounting for the largest share at USD 5.9 billion. This market is poised for significant growth during the forecast period (2024-2034), driven by improved drug uptake, increased disease awareness, and a robust pipeline of innovative therapies. Download the Ulcerative Colitis market report to understand which factors are driving the Ulcerative Colitis therapeutic market @ Ulcerative Colitis Market Trends. The report also provides a detailed epidemiological analysis and forecasts up to 2034, segmented by Total Diagnosed Prevalent Cases of Ulcerative Colitis, Age-specific Cases of Ulcerative Colitis, Severity-specific Cases of Ulcerative Colitis, and Total Treated Patients of Ulcerative Colitis. According to the latest epidemiological analysis, the total diagnosed prevalent cases of ulcerative colitis in the 7MM comprised approximately 3 Million in 2023, with projections indicating continued growth through 2034. The United States contributed the largest share, with approximately 47% of the diagnosed prevalent population, while Germany and Japan each accounted for roughly 10% of the total 7MM patient pool. When examining disease severity, approximately 521K mild cases and 860K moderate to severe cases were identified across these markets. Discover evolving trends in Ulcerative Colitis patient pool forecasts @ Ulcerative Colitis Epidemiology Analysis. The ulcerative colitis treatment market currently encompasses multiple therapeutic approaches, including aminosalicylates, corticosteroids, immunomodulators, biologic therapies, S1P modulators, and Janus kinase inhibitors. Anti-TNF alpha agents remain the recommended first-line treatment option for many patients. Among the currently approved therapies, HUMIRA (AbbVie), REMICADE (Janssen Pharmaceuticals), SIMPONI (Janssen Pharmaceuticals), ENTYVIO (Takeda Pharmaceuticals), XELJANZ (Pfizer), STELARA (Janssen Pharmaceuticals), CAROGRA (EA Pharma/Kissei Pharma), JYSELECA (Gilead Sciences and Galapagos NV), OMVOH (Eli Lilly), SKYRIZI (AbbVie/Boehringer Ingelheim), RINVOQ (AbbVie), and ZEPOSIA (Bristol-Myers Squibb), among others have established strong market positions. By 2034, ENTYVIO is projected to generate the highest revenue in the United States, followed by HUMIRA (AbbVie). In December 2024, Biocon Biologics and Celltrion received FDA approval for their respective biosimilars to STELARA (Janssen Pharmaceuticals) – YESINTEK (Biocon Biologics) and STEQEYMA (Celltrion) – expanding treatment options for patients with ulcerative colitis. In February 2024, the European Commission granted marketing authorization for VELSIPITY (etrasimod) for patients 16 years and older with moderately to severely active ulcerative colitis following its FDA approval in October 2023. The ulcerative colitis therapeutics market is witnessing significant innovation with several emerging therapies such as, Etrasimod (Arena Pharmaceuticals/Pfizer), ABX464 (Abivax), SHR0302 (Reistone Biopharma), Cobitolimod (InDex Pharmaceuticals), TREMFYA (Janssen Pharmaceuticals), BT-11 (Landos Biopharma/NImmune), PRA023 (Merck), Remestemcel-L (Mesoblast), PF-06651600 (Pfizer) and PF-06700841 (Pfizer) among others. Know which Ulcerative Colitis drug is expected to capture the largest market share in 7MM by 2034. Visit the Ulcerative Colitis Insights. Recent developments have further enriched the ulcerative colitis market with several regulatory approvals and clinical advancements. In December 2024, Accropeutics Inc. announced FDA clearance for a Phase II trial of its RIPK2 inhibitor, AC-101, for moderate-to-severe Ulcerative Colitis. Additionally, in November 2024, Johnson & Johnson submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of TREMFYA (guselkumab). In late 2024, AbbVie's SKYRIZI had rapidly outpaced Eli Lilly's OMVOH in the ulcerative colitis market, securing over double the market share just two months post-launch. In January 2025, the FDA granted investigational new drug (IND) clearance for R-5780 (Rise Therapeutics). This innovative therapy leverages gut-regulated immune pathways to enhance the efficacy of immune checkpoint inhibitors, offering a novel approach to treating cancers that are refractory or unresponsive to these therapies. Looking ahead, the ulcerative colitis market is expected to witness significant transformation with the introduction of novel therapeutic classes, including toll-like receptor 9 activators, miR-124 enhancers, and T-cell therapies. While high therapy costs and complications pose challenges, rising awareness, early screening, and advanced treatment strategies are fueling ulcerative colitis treatment market growth. The ulcerative colitis epidemiology and the market landscape present both opportunities and challenges for stakeholders. As treatment paradigms continue to evolve, focusing on personalized medicine and improved patient outcomes, the ulcerative colitis treatment market is positioned for substantial growth, offering new hope for the millions affected by this chronic inflammatory condition worldwide. Table of Contents 1. Key Insights 2. Report Introduction 3. Ulcerative Colitis Market Overview at a Glance 4. Epidemiology and Market Methodology 5. Ulcerative Colitis Executive Summary 6. Ulcerative Colitis Market Disease Background and Overview 7. Ulcerative Colitis Epidemiology and Patient Population 8. Patient Journey 9. Ulcerative Colitis Marketed Therapies 10. Ulcerative Colitis Emerging Drugs 11. Ulcerative Colitis: The 7MM Analysis 12. Ulcerative Colitis Market Access and Reimbursement 13. Ulcerative Colitis KOL Views 14. Ulcerative Colitis SWOT Analysis 15. Ulcerative Colitis Unmet Needs 16. Appendix 17. DelveInsight Capabilities 18. Disclaimer Related Reports Ulcerative Colitis Pipeline Insight Ulcerative Colitis Pipeline Insight provides comprehensive insights about the Ulcerative Colitis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Ulcerative Colitis manufacturers, including Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, and Palatin Technologies, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:

Abivax Announces Closing of $747.5 Million Public Offering

Business Upturn

29-07-2025

Business
Business Upturn

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 American Depositary Shares ('ADSs'), each representing one ordinary share, €0.01 nominal value per share (each an 'Ordinary Share'), of the Company, in the United States (the 'Offering'), which includes the full exercise of the underwriters' option to purchase additional ADSs (the 'Underwriters' Option'). The aggregate gross proceeds, after exercise of the Underwriters' Option, amounted to approximately $747.5 million, equivalent to approximately €637.5 million1, before deduction of underwriting commissions and estimated expenses payable by the Company, and the estimated net proceeds, after deducting underwriting commissions and estimated offering expenses payable by the Company, will be approximately $700.3 million, equivalent to approximately €597.2 million1. All of the ADSs in the Offering were offered by Abivax. The Company believes that the net proceeds from the Offering, together with its current cash and cash equivalents, will allow it to finance its operations into the fourth quarter of 2027, allowing it to reach 12 months of expected cash runway following the planned NDA submission for Ulcerative Colitis, assuming positive results from its Phase 3 maintenance trial. Abivax's Ordinary Shares are listed on the regulated market of Euronext Paris under the symbol 'ABVX' and its ADSs are listed on the Nasdaq Global Market under the symbol 'ABVX'. Leerink Partners, Piper Sandler & Co. and Guggenheim Securities acted as joint bookrunning managers for the Offering. LifeSci Capital acted as lead manager, with BTIG and Van Lanschot Kempen acting as co-managers for the Offering. An automatic shelf registration statement on Form F-3 (including a prospectus) relating to the Company's securities was filed with the Securities and Exchange Commission (the 'SEC') on July 23, 2025 and became effective upon filing. The Company has also filed with the SEC a final prospectus supplement (and accompanying prospectus) relating to and describing the terms of the Offering (the 'Final Prospectus Supplement'). These documents may be obtained free of charge by visiting EDGAR on the SEC's website at Alternatively, a copy of the Final Prospectus Supplement (and accompanying prospectus) may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; or from Piper Sandler & Co., 350 North 5th Street, Suite 1300, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at 800-747-3924 or by email at [email protected]; or from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at [email protected]. ***** About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Contacts: Abivax Investor RelationsPatrick Malloy [email protected] +1 847 987 4878 ***** Forward-Looking Statements This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company's business and financial objectives. Words such as 'design,' 'intend,' 'expect,' 'forward,' 'future,' 'can,' 'could,' 'may,' 'might,' 'potential,' 'plan,' 'project,' 'should,' 'will' and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the anticipated use of net proceeds from the Offering, the period of time through which the Company anticipates its financial resources will be adequate to support its operations, timing of planned NDA submission, as well as statements concerning or implying the therapeutic potential of Abivax's drug candidates, clinical development plans, business and regulatory strategy, and anticipated future performance and other statements that are not historical fact. Although Abivax's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the AMF pursuant to its legal obligations, including its universal registration document ( Document d'Enregistrement Universel ), and in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption 'Risk Factors.' These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates and the availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. Disclaimers This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions. This announcement is not a prospectus within the meaning of the Prospectus Regulation. In relation to each member state of the European Economic Area (each, a 'Relevant Member State'), an offer of the securities referred to herein is not being made and will not be made to the public in that Relevant Member State, other than (i) to any legal entity which is a qualified investor as defined in the Prospectus Regulation, (ii) to fewer than 150 natural or legal persons per Relevant Member State; or (iii) in any other circumstances falling within Article 1(4) of the Prospectus Regulation; provided that no such offer of the securities referred to herein shall require the Company to publish a prospectus pursuant to Article 3 of the Prospectus Regulation. For the purposes of the above, the expression an 'offer to the public' in any Relevant Member State shall have the meaning ascribed to it in Article 2(d) of the Prospectus Regulation. This communication is being distributed only to, and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), and (c) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as 'relevant persons'). Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents. Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the securities offered in the Offering has led to the conclusion in relation to the type of clients criteria only that: (i) the type of clients to whom the securities are targeted is eligible counterparties and professional clients only, each as defined in Directive 2014/65/EU, as amended ('MiFID II'); and (ii) all channels for distribution of the securities offered in the Offering to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Ordinary Shares (a 'distributor') should take into consideration the manufacturers' type of clients assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Ordinary Shares offered in the Offering (by either adopting or refining the manufacturers' type of clients assessment) and determining appropriate distribution channels. This press release has been prepared in both French and English. In the event of any discrepancies between the two versions of the press release, the French language version shall prevail. 1 Based on an exchange rate of €1.00 = $1.1726 as published by the European Central Bank on July 23, 2025. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

From protein goals to fibremaxxing: Are these health trends any good?

Business Standard

14-07-2025

Health
Business Standard

From protein goals to fibremaxxing: Are these health trends any good?

For years, social media—particularly TikTok and Instagram —has been obsessed with hitting protein goals. However, recently, a new trend has emerged: Fibre goals and the rise of 'fibremaxxing'. While these trends are often shared by fitness influencers or wellness creators, it's important to understand what's rooted in science and what might be just another passing fad. Why protein goals became popular—and when they're overdone Protein goals became popular for a good reason: protein helps build and repair muscles, supports metabolism, and promotes satiety (the feeling of fullness). According to Harvard Health Publishing, the average adult needs about 0.8 grams of protein per kilogram of body weight per day. That's roughly 50–60 grams daily for someone who weighs around 70 kg. Despite the hype, most people already get enough protein from their regular diet. Overconsumption of protein supplements or shakes may not provide extra benefits for the average person and could stress the kidneys in some cases. Is fibremaxxing actually good for your gut? The new trend of 'fibremaxxing' is where users try to meet or exceed daily fibre recommendations. It has gone viral in recent months. Videos showing high-fibre meals, gut health smoothies, and hacks are now gaining traction under hashtags like #fibregoals and #guthealth. Dr Partap Chauhan, founder and director of Jiva Ayurveda, says, 'Fibre is having its moment on social media, and rightly so—but the science is not new. Fibre-rich foods like seasonal fruits, whole grains, lentils, and vegetables have always been considered essential for good gut health. The shift from protein obsession to fibre awareness is a welcome one, but the real challenge lies in personalised application. Your body type, digestion, and daily routine must guide your diet, not online trends.' The CDC recommends that adults eat 22 to 34 grams of fibre each day, depending on age and sex. A sudden increase in fibre can lead to digestive discomfort like bloating, gas, constipation, diarrhoea, or cramps. Debalina Dutta, dietician at CMRI Hospital, says that while increasing fibre intake poses little risk for healthy individuals, it may not be suitable for those with conditions such as Irritable Bowel Syndrome (IBS), Crohn's disease, Ulcerative Colitis, cholera, or bowel obstruction. What is the Balkan breakfast trend on social media? The Balkan breakfast trend is all over social media, with videos showing plates full of eggs, tomatoes, cucumbers, olives, feta cheese, and bread. Creators claim it's a hearty, healthy, and balanced way to start the day. According to a report by National Geographic, Balkan breakfasts are far more diverse than portrayed. In summer, plates brim with fresh produce; winter meals might feature porridges such as buckwheat or polenta. While nutritionists say this meal is balanced, nutrient-rich, and high in fibre, protein, and healthy fats, they recommend swapping white bread for whole wheat, limiting cured meat, and adding more vegetables. Those watching sodium or fat intake should go easy on the cheese and olives. ' Nutrition is very personal, as what is good and might work for one individual may not be ideal for another based on age, medical conditions, activity level, and food preferences. An effective and safe strategy is a balanced, varied, and nutrient-rich diet aimed at overall wellness,' added Dr Srishti Goyal, dietician at Ujala Cygnus Group of Hospitals. Are super greens powders better than real vegetables? Super greens powders claim to provide concentrated doses of nutrients from spinach, kale, spirulina, and more—all in a scoop. But are they better than eating real vegetables? According to a report by Indian Express, these powders help fill nutritional gaps, especially for picky eaters or people with digestive issues. However, some powders may contain added sugars, preservatives, or interfere with medications. 'The best thing to do is listen to qualified professionals and always check if the advice comes from a reliable source. Just focus on real, wholesome food, eat in the right amounts, and enjoy what you eat. That's the best way to stay healthy in the long run,' said Sowjanya Reddy, Senior Dietitian, CARE Hospitals, Hyderabad. Should you drink water first thing in the morning? Another trending morning ritual is drinking 1–2 glasses of water right after waking up—before tea, coffee, or breakfast. As per Dr Sonia Bhatt from Apollo Hospitals, this habit may help flush out toxins and kickstart digestion, promoting healthy metabolism. She adds, 'Lukewarm water is gentler on the stomach, especially if you have acidity or digestive issues. And while drinking water is in general a good habit, drinking more than 4 litres every day continuously might stress out your system.' Can raw carrot salad really balance hormones? This quirky trend recommends eating a raw carrot salad (with vinegar, salt, and coconut oil) once daily to balance hormones—especially oestrogen in women. TikTok users say it improves skin, mood, and PMS symptoms. The trend is credited to Dr Ray Peat, an American biologist and thyroid expert, who claims raw carrot fibre can reduce excess oestrogen, ease migraines, and alleviate PMS symptoms. His observations, based on self-reports and small samples, suggest oestrogen levels dropped within days of adopting the carrot diet. Experts say that the fibre, antioxidants, and other nutrients in carrots do benefit health. It should not be treated as a 'miracle food'. If you have hormonal imbalances, consult a healthcare provider. 'Aim for 4–5 daily servings of colourful fruits and vegetables, which consist of fibre, vitamins, antioxidants, and hydration essential for gastrointestinal health and disease prevention. Choose whole grains like brown rice, oats, quinoa, and millet instead of refined carbohydrates, which contain complex carbohydrates, B vitamins, and fibre that will control blood sugar and keep you satiated. Include high-quality protein food items like legumes, fish, poultry, eggs, tofu, dairy, and nuts to maintain muscle health, immunity, and satiety, while keeping animal-based proteins lean and portion-controlled,' explained Dr Goyal. How do you know if a diet trend is right for you? Dr Chauhan recommends asking three simple questions before following any advice:

Managing Ulcerative Colitis: Why Lifestyle Remedies Aren't Always Enough

Health Line

10-07-2025

Health
Health Line

Managing Ulcerative Colitis: Why Lifestyle Remedies Aren't Always Enough

Ulcerative colitis (UC) is a chronic disease that causes inflammation and sores in the lining of your colon. It's a complicated disease that can interfere with your quality of life. Ulcerative colitis (UC) can significantly affect your quality of life. You may miss work or school and feel limited by the kinds of activities you can do because of urgent bowel activity. However, remission is possible with UC. Lifestyle changes and certain supplements may make you feel better. Medications and a smart treatment plan may reduce your risk of serious complications and allow you to experience longer periods of remission in a way that lifestyle changes alone cannot. Read on to learn more about the role of lifestyle changes in UC and the reasons for considering medical treatments in the long run. Role of lifestyle changes and supplements UC affects people differently, so you may see an improvement in your condition with lifestyle changes and supplements. These lifestyle changes aren't meant to replace a medication regimen. Talk with a doctor to see if adding these to your daily routine is safe and advisable. Diet doesn't cause UC, but avoiding certain foods may lessen the severity of flare-ups and reduce symptoms. These include greasy foods and vegetables that cause gas, like cauliflower and broccoli. Avoiding high fiber foods, lactose, and caffeine may also improve your symptoms. A 2023 paper states that dietary changes can help reduce symptoms of UC. Some people with UC notice positive changes resulting from light exercise, relaxation techniques, and breathing exercises. These activities may reduce stress levels and help you cope with flare-ups. Some nutritional supplements may also be helpful. Studies have shown that taking fish oil and probiotics may have a role in helping people with UC. Fish oil may help reduce inflammation, and probiotics can add good bacteria to your intestinal tract. While lifestyle changes and supplements may help ease symptoms, they aren't enough to manage UC alone. UC is a chronic condition that can lead to serious complications without proper medical treatment. The primary goal of care is achieving and maintaining remission, which typically requires prescribed therapies alongside supportive measures. Here are some reasons why you can speak with your doctor or gastroenterologist about prescription medications and treatment. Ulcerative colitis complications Lifestyle changes and supplements may not control flare-ups as effectively as prescription medications. As a result, you may continue to have repeated bouts of diarrhea and bloody stool. The more attacks you have, the greater risk you have for complications and the more inflammation you'll experience. Research shows that inflammation plays a key role in the development of colorectal cancer in people with UC. Sores or ulcers in the lining of your colon can bleed and lead to bloody stools, while long-term intestinal bleeding can cause iron deficiency anemia. Symptoms of this condition include dizziness, fatigue, and lightheadedness. Your doctor can recommend iron supplements to correct this deficiency, but it's also important to treat the underlying cause of bleeding. A prescription medication for UC can stop inflammation and heal ulcers in your colon. Chronic diarrhea from UC can also cause problems. Diarrhea can decrease your fluid levels, causing dehydration and electrolyte imbalances. Signs of dehydration include: excessive thirst low urine output headaches dry skin dizziness confusion Drinking more fluids can counter the effects of diarrhea. However, medication can treat the source of the inflammation to control symptoms and stop repeated relapses. Drug therapies There isn't a cure for UC, but remission can make it feel like the condition is no longer affecting your daily life. Several medications are available to help reduce flare-ups and keep symptoms at bay. Talk with your healthcare team about your options. With the right treatment, many people go months or even years with no symptoms. Prescription medications and drug therapies to help manage UC include: Aminosalicylates (5-ASAs): Used primarily for mild to moderate UC, these drugs reduce inflammation in the lining of the colon. Options include sulfasalazine (Azulfidine), mesalamine (Pentasa), olsalazine (Dipentum), and balsalazide (Colazal, Giazo). This class of drugs is also recommended for maintenance treatment to help prevent flare-ups. Tofacitinib (Xeljanz): This is a newer option in a class of medications called Janus kinase (JAK) inhibitors. It works in a unique way to reduce inflammation in people with moderate to severe UC. Corticosteroids: Prescribed for moderate to severe flare-ups, this class of drugs, including prednisone or budesonide, reduces inflammation by suppressing the immune system. Because of potential side effects, they're typically not intended for long-term or maintenance use. Immunomodulators: These medications, also for moderate to severe symptoms, help suppress the immune response and are often used in conjunction with a corticosteroid. A few options include azathioprine (Azasan, Imuran), tacrolimus (Prograf), and 6-mercaptopurine. Biologics: Used for moderate to severe UC that doesn't respond to other treatments, these injections or infusions block the proteins that cause inflammation in your colon. Examples include: anti-TNF agents such as adalimumab (Humira), infliximab (Remicade), golimumab (Simponi) integrin receptor antagonists such as vedolizumab (Entyvio) IL-12/23 inhibitors such as ustekinumab (Stelara) Targeted synthetic small molecules and JAK inhibitors: The first oral JAK inhibitor approved for UC in 2023 by the Food and Drug Administration (FDA), tofacitinib (Xeljanz) is used in moderate to severe cases, particularly when other biologics haven't worked. Newer JAK inhibitors like upadacitinib (Rinvoq) have also been approved more recently. These drugs fall under a broader class known as targeted synthetic small molecules, which also includes newer options like ozanimod (Zeposia) and etrasimod (Velsipity). These medications work by selectively modulating immune pathways involved in inflammation. Newer biologics such as risankizumab-rzaa (Skyrizi), mirikizumab-mrkz (Omvoh), and guselkumab (Tremfya) are also emerging options for people whose UC hasn't responded to older therapies. Surgery is another option, but only as a last resort in severe cases. Surgeons will remove the entire colon in the case of colon rupture or uncontrolled bleeding. High cancer risk is another reason surgery may be recommended. Although the procedure can cure UC, it requires a permanent ileostomy, or creation of a J-pouch. An ileostomy is when the end of the small intestine is connected to an opening in the belly, called a stoma. Waste comes out through this opening into a special bag that sticks to the skin. It's a new way for the body to get rid of waste in the colon's absence. Reduce the risk of colorectal cancer Colorectal cancer is a significant complication of UC. The risk of developing this type of cancer depends on the severity of your symptoms and how long you've had the disease. However, remission may cut your risk of cancer. Lifestyle changes and nutritional supplements aren't meant to replace any recommendations or prescriptions from your doctor. When taken as directed, medications reduce inflammation in your colon and help you achieve remission sooner. The longer your disease remains in remission, the less likely you are to develop colon cancer and precancerous cells. Being under the supervision of a specialist also gives your gastroenterologist the opportunity to monitor your condition over time and schedule appropriate screenings. Once you're diagnosed with UC, you'll need to receive periodic colon cancer screenings — how often depends on your own health and family history.